
Eurofins Expands CDMO Capabilities in North America with New Canadian Facility
Eurofins CDMO Alphora Inc., based in Canada, has unveiled its Biologics initiative as part of its strategic plan to expand and diversify its presence in the contract development and manufacturing industry within North America. The multiphase initiative centers around establishing a new facility in Mississauga, ON, Canada. The first phase, slated for completion by December 2023, will encompass a 3,300 square foot pilot-scale facility with a focus on mammalian cell culture (mAbs) and therapeutic proteins, offering non-cGMP process development and up to 200L scale production. The endeavor is backed by a substantial $6.3 million investment from Eurofins CDMO Alphora, with additional support in the form of a $2.5 million grant from the Ontario Government through the Ontario Together Fund (OTF).
The Biologics initiative will encompass a wide range of offerings, including analytical, upstream, and downstream development, process design and gap analysis, process scale-up, bioassays, as well as cGMP quality documentation. The upstream processing laboratories will be equipped with cutting-edge technology capable of accommodating diverse batch sizes for multiple mammalian and avian cell lines. Moreover, Eurofins CDMO Alphora’s existing expertise in small molecule drug development, production, and analytical development since 2003 will be leveraged to support clients with antibody drug conjugate candidates.
Eurofins Scientific, is a rapidly growing global laboratory and contract research organization with a widespread international network comprising approximately 900 laboratories located across 61 countries. The company has conducted over 450 million tests in aggregate. They comprise approximately 4% of global laboratory diagnostic revenue. The company has been actively increasing its investments in BioPharma-related genomic services.